172 related articles for article (PubMed ID: 36752022)
1. Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis.
Stascheit F; Chuquisana O; Keller CW; Ambrose PA; Hoffmann S; Gross CC; Lehnerer S; Wiendl H; Willcox N; Meisel A; Lünemann JD
Eur J Neurol; 2023 May; 30(5):1409-1416. PubMed ID: 36752022
[TBL] [Abstract][Full Text] [Related]
2. Increased complement consumption in MuSK-antibody-positive myasthenia gravis patients.
Tüzün E; Yılmaz V; Parman Y; Oflazer P; Deymeer F; Saruhan-Direskeneli G
Med Princ Pract; 2011; 20(6):581-3. PubMed ID: 21986021
[TBL] [Abstract][Full Text] [Related]
3. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
Leite MI; Jacob S; Viegas S; Cossins J; Clover L; Morgan BP; Beeson D; Willcox N; Vincent A
Brain; 2008 Jul; 131(Pt 7):1940-52. PubMed ID: 18515870
[TBL] [Abstract][Full Text] [Related]
4. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
Shiraishi H; Motomura M; Yoshimura T; Fukudome T; Fukuda T; Nakao Y; Tsujihata M; Vincent A; Eguchi K
Ann Neurol; 2005 Feb; 57(2):289-93. PubMed ID: 15668981
[TBL] [Abstract][Full Text] [Related]
5. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis.
Nakata R; Motomura M; Masuda T; Shiraishi H; Tokuda M; Fukuda T; Ando T; Yoshimura T; Tsujihata M; Kawakami A
Eur J Neurol; 2013 Sep; 20(9):1272-6. PubMed ID: 23679930
[TBL] [Abstract][Full Text] [Related]
6. [Antibodies in myasthenia gravis].
Eymard B
Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
[TBL] [Abstract][Full Text] [Related]
7. Activation of the classical complement pathway in myasthenia gravis with acetylcholine receptor antibodies.
Ozawa Y; Uzawa A; Onishi Y; Yasuda M; Kojima Y; Kuwabara S
Muscle Nerve; 2023 Nov; 68(5):798-804. PubMed ID: 37705312
[TBL] [Abstract][Full Text] [Related]
8. Complement associated pathogenic mechanisms in myasthenia gravis.
Tüzün E; Christadoss P
Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
[TBL] [Abstract][Full Text] [Related]
9. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
[TBL] [Abstract][Full Text] [Related]
10. Complement and cytokine based therapeutic strategies in myasthenia gravis.
Tüzün E; Huda R; Christadoss P
J Autoimmun; 2011 Sep; 37(2):136-43. PubMed ID: 21636248
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies in Japanese patients with ocular myasthenia gravis.
Nagaishi A; Narita T; Woodhall M; Jacobson L; Waters P; Irani SR; Vincent A; Matsuo H
Muscle Nerve; 2021 Feb; 63(2):262-267. PubMed ID: 33094484
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis.
Nikolic A; Djukic P; Basta I; Hajdukovic Lj; Stojanovic VR; Stevic Z; Nikolic D; Bozic V; Lavrnic S; Lavrnic D
Clin Neurol Neurosurg; 2013 Apr; 115(4):432-7. PubMed ID: 22770539
[TBL] [Abstract][Full Text] [Related]
13. Complement activation in myasthenia gravis plasma by Torpedo acetylcholine receptor liposomes.
DuPont BL; Koethe SM; McQuillen MP
Immunol Invest; 1985 Oct; 14(5):415-20. PubMed ID: 4077155
[TBL] [Abstract][Full Text] [Related]
14. The high frequency and clinical feature of seronegative myasthenia gravis in Southern China.
Feng HY; Wang HY; Liu WB; He XT; Huang X; Luo CM; Li Y
Neurol Sci; 2013 Jun; 34(6):919-24. PubMed ID: 22829131
[TBL] [Abstract][Full Text] [Related]
15. Characteristics Of acetylcholine-receptor-antibody-negative myasthenia gravis in a South African cohort.
Huda S; Woodhall MR; Vincent A; Heckmann JM
Muscle Nerve; 2016 Dec; 54(6):1023-1029. PubMed ID: 27105303
[TBL] [Abstract][Full Text] [Related]
16. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
Vincent A; Leite MI
Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
[TBL] [Abstract][Full Text] [Related]
17. Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities.
Rose N; Holdermann S; Callegari I; Kim H; Fruh I; Kappos L; Kuhle J; Müller M; Sanderson NSR; Derfuss T
Acta Neuropathol; 2022 Nov; 144(5):1005-1025. PubMed ID: 36074148
[TBL] [Abstract][Full Text] [Related]
18. Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy.
Iacomino N; Vanoli F; Frangiamore R; Ballardini M; Scandiffio L; Bortone F; Andreetta F; Baggi F; Bernasconi P; Antozzi C; Cavalcante P; Mantegazza R
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740382
[TBL] [Abstract][Full Text] [Related]
19. Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis.
Aurangzeb S; Tariq M; Irshad M; Badshah M; Khan RS
J Pak Med Assoc; 2009 May; 59(5):289-92. PubMed ID: 19438131
[TBL] [Abstract][Full Text] [Related]
20. Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome.
Kojima Y; Uzawa A; Ozawa Y; Yasuda M; Onishi Y; Akamine H; Kawaguchi N; Himuro K; Noto YI; Mizuno T; Kuwabara S
J Neurol Neurosurg Psychiatry; 2021 Sep; 92(9):963-968. PubMed ID: 33766920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
